Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

This study has been terminated.
(Study was terminated early for business reasons (not safety reasons).)
Information provided by:
Vericel Corporation Identifier:
First received: November 24, 2008
Last updated: March 7, 2017
Last verified: March 2017
The hypothesis is that Aastrom TRC autologous bone marrow tissue "grafts" can be safely used to promote bone healing as part of a single level posterolateral spine fusion surgical procedure.

Condition Intervention Phase
Single Level Posterolateral Spinal Fusion
Biological: Bone Repair Cells (BRCs)
Procedure: Autologous bone graft
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

Resource links provided by NLM:

Further study details as provided by Vericel Corporation:

Primary Outcome Measures:
  • The primary objective is to confirm that the TRC product, when used as a bone graft, is safe for use in posterolateral lumbar spinal fusion surgery, on the basis of defined radiographic evidence of bone fusion. [ Time Frame: Throughout duration of study ]

Secondary Outcome Measures:
  • To assess the relative efficacy of TRC graft compared to autologous vertebral bone graft based on the frequency and extent of callus or bone bridging between the adjacent decorticated vertebral processes on each side of the vertebrae. [ Time Frame: Imaged by CT at 6 months after surgery ]
  • To assess surgeon's evaluation of radiographic healing at the site of surgery based on flexion and extension radiographs, as well as 2AP and lateral radiographs, and of clinical resolution [ Time Frame: Baseline, Month 6 and Month 12 ]
  • To assess reduction in pain scores at site of back surgery [ Time Frame: First 3 months post-treatment ]
  • To assess use of prescription and non-prescription pain control and other drugs in treatment patients as compared to control patients [ Time Frame: Throughout duration of study ]
  • To assess restoration of function for return to activities of normal daily living [ Time Frame: Month 6 and Month 12 ]

Enrollment: 2
Study Start Date: April 2006
Study Completion Date: October 2008
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Control
The Control arm of the study will receive bone autograft.
Procedure: Autologous bone graft
Experimental: Treatment
The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
Biological: Bone Repair Cells (BRCs)
BRCs will be administered during spine fusion surgery
Other Name: autologous bone marrow cells


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults, 18-75 years of age
  • Identified as eligible for elective surgery for single (1) level, posterolateral spinal fusion between L1 and S1 in which the spine stabilization is accomplished by pedicle screws and rod.
  • Male patients and female patients (not pregnant or lactating). Patients should use an appropriate form of contraception while participating in the study.
  • Patients able to give informed consent.
  • Normal organ and marrow function

Exclusion Criteria:

  • Patients with hypophosphatasia, primary or secondary hyperparathyroidism caused by chronic renal insufficiency or osteomalacia.
  • Patients with osteoporotic vertebral fractures.
  • Patients with a prior spinal fusion at the level to be treated.
  • Concomitant use of BMP, or devices containing BMP, or electronic growth stimulators.
  • Any active infection of any clinical significance will be excluded from the study.
  • Positive for HIV, HTLV and/or syphilis.
  • Active Hepatitis B, or Hepatitis C infection at the time of enrollment.
  • Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the ex-vivo cell production process.
  • Patients who require systemic corticosteroid therapy after surgery.
  • Pregnancy or lactation; positive of hCG.
  • Body Mass Index (BMI) of 40 Kg/m2 or greater.
  • Patients unable to tolerate general anesthesia defined as an ASA criteria of >2.
  • Patients with poorly controlled diabetes mellitus (HbA1C >7%).
  • Rationale for Exclusion of Certain Study Candidates

    1. Patients with other diseases are excluded to avoid confounding factors that might impact evaluation of safety and efficacy of TRC cell therapy in posterolateral spine fusion.
    2. More extensive surgery requiring more than one (1) level fusion is contraindicated in this study, to avoid confounding factors that might impact evaluation of safety and efficacy of TRC cell therapy.
  • In the opinion of the investigator, the patient is unsuitable to cellular therapy or unable to continue with this study.
  • Patients that drink more than 2 alcoholic drinks per day or have a history of illicit drug use at the time of enrollment shall not be enrolled in the study.
  • Patient known to be non-euthyroid at baseline.
  • Patients undergoing active cancer therapy.
  • Bisphosphonate Therapy

    1. Patients that have undergone bisphosphonate therapy within the last 10 years.
    2. Initiation of bisphosphonate therapy in patients during this study is prohibited.
  • Patients with a known diagnosis of osteoporosis with recorded BMD less than -2.5.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00797550

Sponsors and Collaborators
Vericel Corporation
Principal Investigator: Harry Herkowitz, MD William Beaumont Hospitals
  More Information

Responsible Party: Elmar Burchardt, MD, PhD, Aastrom Biosciences, Inc. Identifier: NCT00797550     History of Changes
Other Study ID Numbers: ABI-55-0509-1
Study First Received: November 24, 2008
Last Updated: March 7, 2017

Keywords provided by Vericel Corporation:
posterolateral spine fusion
bone graft processed this record on April 27, 2017